Generic Harvoni ( Ledipasvir / Sofosbuvir )

Order cheap Generic Harvoni (Ledipasvir / Sofosbuvir) without dr prescription in the United States

At our pharmacy, you can purchase Harvoni without a prescription, with delivery throughout the USA within 5-14 days. Discreet and anonymous packaging.
Harvoni is used for the treatment of chronic hepatitis C virus (HCV) infection, specifically for genotypes 1, 4, 5, and 6. The medication is a fixed‑dose combination of ledipasvir (an NS5A inhibitor) and sofosbuvir (a nucleotide polymerase inhibitor) that directly blocks viral replication, achieving cure (sustained virological response) without the need for interferon or ribavirin in most patients.
The usual dosage of Harvoni is one tablet (90 mg ledipasvir / 400 mg sofosbuvir) taken once daily, with or without food.
The administration form is film‑coated tablets.
The effect of the medication begins within several days to weeks, with undetectable viral load typically achieved after 4‑8 weeks of treatment.
The duration of action is typically 8 to 12 weeks, depending on the HCV genotype, presence of cirrhosis, and prior treatment history.
Alcohol consumption is not recommended during treatment.
The most common side effects are headache and fatigue.
Would you like to try Harvoni without a prescription?

Basic Harvoni Information

• INN (International Nonproprietary Name): Ledipasvir / Sofosbuvir
• Brand names available in USA: Harvoni®
• ATC Code: J05AP51
• Forms and dosages: Film‑coated tablets – 90 mg ledipasvir / 400 mg sofosbuvir
• Manufacturers in USA: Gilead Sciences, Inc.
• Registration status in USA: Approved by FDA (2014)
• OTC / Rx classification: Prescription only (Rx)

Mechanism and Pharmacology

Harvoni contains two direct‑acting antivirals: ledipasvir, which inhibits the HCV NS5A protein (essential for viral RNA replication and assembly), and sofosbuvir, a nucleotide analog inhibitor of the HCV NS5B RNA‑dependent RNA polymerase (acts as a chain terminator). The combination blocks multiple steps of the HCV life cycle, with a high barrier to resistance and pan‑genotypic activity (approved for genotypes 1, 4, 5, 6; also used off‑label for genotype 3 with ribavirin). Sofosbuvir is metabolized in the liver to its active triphosphate; ledipasvir is metabolized by unknown mechanisms but is a substrate of P‑gp and breast cancer resistance protein (BCRP).

Indications and Usage

Harvoni is indicated for the treatment of chronic hepatitis C virus infection in adults and pediatric patients (≥3 years of age, weighing at least 17 kg) with HCV genotype 1, 4, 5, or 6 infection, without cirrhosis or with compensated cirrhosis (Child‑Pugh A). It is also indicated for patients with HCV/HIV‑1 coinfection and for patients with decompensated cirrhosis (Child‑Pugh B/C) when used in combination with ribavirin. Harvoni is also approved for post‑liver transplant patients with no cirrhosis or compensated cirrhosis.

Critical Warnings and Limitations

High‑Risk Groups
Elderly: No dose adjustment required based solely on age; use with caution in patients with significant renal impairment.
Pregnancy: Insufficient data in pregnant women. When used with ribavirin, ribavirin is teratogenic – effective contraception required for both male and female patients during and for 6 months after therapy. For Harvoni alone, use only if potential benefit justifies potential risk.
Breastfeeding: Unknown whether ledipasvir or sofosbuvir passes into breast milk; advise caution.

Activity Interactions
Driving: May cause fatigue or dizziness – use caution when operating vehicles or machinery.
Alcohol: Avoid alcohol consumption as it may worsen liver damage and reduce treatment adherence.

Dosage Guide

Standard Regimens
One tablet (90 mg ledipasvir / 400 mg sofosbuvir) taken orally once daily with or without food.
Treatment duration:
- Genotype 1, without cirrhosis or with compensated cirrhosis: 8 weeks (if treatment‑naïve with baseline HCV RNA - Genotype 4, 5, 6, without cirrhosis or with compensated cirrhosis: 12 weeks.
- Genotype 1, treatment‑experienced (including prior protease inhibitor failure): 12 weeks.
- Decompensated cirrhosis (Child‑Pugh B/C): 12 weeks + ribavirin (weight‑based).
- Post‑liver transplant, no cirrhosis or compensated cirrhosis: 12 weeks.
- Pediatric (≥3 years, ≥17 kg): weight‑based dosing using appropriate dosage forms.

Special Populations
Renal impairment: For eGFR ≥30 mL/min, no dose adjustment. For eGFR Hepatic impairment: No dose adjustment for mild, moderate, or severe (Child‑Pugh A, B, C) impairment.
Pediatric: Dosing based on weight; refer to prescribing information.

Side Effects and Contraindications

Common side effects:
- Headache
- Fatigue
- Nausea
- Diarrhea
- Insomnia
- Upper respiratory tract infection

Serious side effects requiring medical attention:
- Symptomatic bradycardia when coadministered with amiodarone (especially with sofosbuvir)
- Hepatitis B reactivation in patients coinfected with HBV and HCV (screen all patients for HBV)
- Severe allergic reactions (rash, angioedema)
- Depression or suicidal ideation (rare)

Absolute contraindications:
- Hypersensitivity to ledipasvir, sofosbuvir, or any excipient.
- Coadministration with potent P‑gp inducers (e.g., rifampin, St. John’s wort, carbamazepine) – contraindicated due to reduced levels of sofosbuvir and ledipasvir.
- For regimens containing ribavirin: pregnancy, severe renal impairment (eGFR

Drug Interactions

Significant interactions include:
- Potent P‑gp inducers (rifampin, carbamazepine, phenytoin, St. John’s wort): Decrease sofosbuvir/ledipasvir levels – contraindicated.
- Amiodarone: Risk of severe bradycardia and heart block – avoid coadministration or monitor closely.
- Antacids (aluminum/magnesium) and H2 blockers (famotidine, ranitidine): Reduce ledipasvir absorption; separate administration by at least 4 hours.
- Proton pump inhibitors (omeprazole, esomeprazole, etc.): Can significantly reduce ledipasvir exposure; avoid concurrent use if possible. If unavoidable, take Harvoni with food and administer PPIs simultaneously (max dose equivalent to omeprazole 20 mg).
- Statins (rosuvastatin, atorvastatin, etc.): Ledipasvir/sofosbuvir may increase statin levels; monitor for myopathy and consider lower statin doses.
- Other HCV direct‑acting antivirals: Not recommended unless studied.

Practical Guidelines

Administration
Take Harvoni once daily at the same time each day, with or without food. Swallow tablet whole; do not crush or chew. If a dose is missed within 18 hours of the usual time, take it as soon as possible; if more than 18 hours have passed, skip the missed dose and take the next at the regular time. Do not double dose. Complete the full prescribed course to achieve cure.

Monitoring
Regular blood tests required before and during treatment:
- HCV RNA viral load (baseline, week 4, end of treatment, and 12 weeks post‑treatment)
- Liver function tests (ALT, AST, bilirubin)
- Renal function (creatinine, eGFR)
- HBV screening (HBsAg, anti‑HBc) to detect risk of reactivation
- Pregnancy test for women of childbearing potential (if ribavirin is used)

Storage
Store at room temperature (20‑25°C / 68‑77°F), excursions permitted to 15‑30°C (59‑86°F). Protect from moisture and heat. Keep tablets in original bottle with desiccant; do not remove desiccant. Close tightly after each use.

Alternative Medications

• Epclusa (sofosbuvir/velpatasvir): Pan‑genotypic, 12‑week treatment, no need for ribavirin in most patients.
• Mavyret (glecaprevir/pibrentasvir): Pan‑genotypic, 8‑week treatment for non‑cirrhotic patients.
• Vosevi (sofosbuvir/velpatasvir/voxilaprevir): For retreatment after prior DAA failure.
• Zepatier (elbasvir/grazoprevir): For genotypes 1 and 4; requires baseline resistance testing.
• Daklinza (daclatasvir) + sofosbuvir: For genotypes 1‑4; limited use.

Clinical Effectiveness

In pivotal clinical trials (ION‑1, ION‑2, ION‑3), Harvoni achieved SVR12 rates of 94‑99% in treatment‑naïve and treatment‑experienced patients with HCV genotype 1, with 8‑12 weeks of therapy. For genotype 4, SVR12 rates were 93‑96%. For genotype 5 and 6, limited data show high efficacy (95‑100%). In patients with compensated cirrhosis, SVR12 rates were 94‑98%. In decompensated cirrhosis (Child‑Pugh B/C), the addition of ribavirin for 12 weeks resulted in SVR12 rates of 85‑87%. Harvoni is highly effective, well‑tolerated, and has a low risk of resistance (less than 1% in clinical trials).

Important: Harvoni requires medical supervision and should only be used under prescription. Do not stop treatment without consulting your doctor. Complete the full course as prescribed to achieve cure. Regular monitoring for HBV reactivation and drug interactions is essential. If you experience signs of bradycardia (dizziness, fainting, chest pain) while on amiodarone, seek immediate medical attention.

How to buy Generic Harvoni no prescription U.S. Online Pharmacy